• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Genome and Immune Profiling of Inflammatory Breast Cancer
Inflammatory breast cancer (IBC) is a rare and aggressive form of breast cancer that remains poorly understood at the molecular level. Comprehensive tumor profiling was performed to understand clinically actionable alterations in IBC. Targeted next-generation sequencing (NGS) and IHC were performed to identify activated pathways in IBC tumor tissues. siRNA studies examined the impact of IBC genomic variants in cellular models. IBC tumor tissues were further characterized for immune infiltration and immune checkpoint expression by IHC. Genomic analysis identified recurrent alterations in core biologic pathways, including ac...
Source: Molecular Cancer Therapeutics - July 4, 2016 Category: Cancer & Oncology Authors: Hamm, C. A., Moran, D., Rao, K., Trusk, P. B., Pry, K., Sausen, M., Jones, S., Velculescu, V. E., Cristofanilli, M., Bacus, S. Tags: Companion Diagnostics and Cancer Biomarkers Source Type: research

Abstract P5-04-02: The histone deacetylase inhibitor entinostat enhances the efficacy of the MEK inhibitor pimasertib against aggressive types of breast cancer through Noxa-mediated myeloid cell leukemia 1 degradation
Purpose: Inflammatory breast cancer (IBC) and triple-negative breast cancer (TNBC) are the two most aggressive types of breast cancer whose molecular mechanisms remain unclear, representing a challenge for the development of effective targeted therapies. Single agent targeted therapies are of limited effectiveness in these types of breast cancer. Therefore, we aim to identify new combination therapeutic candidates for these aggressive diseases by comprehensive genomic screening.Experimental Design: We screened kinome siRNA libraries with the mitogen/extracellular signal-regulated kinase (MEK) inhibitor [pimasertib], and ge...
Source: Cancer Research - February 18, 2016 Category: Cancer & Oncology Authors: Torres-Adorno, A., Lee, J., Kogawa, T., Bartholomeusz, C., Pitner, M., Ordentlich, P., Lim, B., Tripathy, D., Ueno, N. Tags: Poster Session Abstracts Source Type: research

Abstract 680: Identification of GLI1 antagonists for breast cancer therapy
Conclusion: Several agents showed efficacy in in vitro BC cancer models demonstrating that GLI inhibitors may be a valid therapeutic approach for targeting GLI-dependent BC cancers.[1] Z. Thomas, W. Gibson, J. Sexton, K. Aird, S. Ingram, A. Aldrich, H. Lyerly, G. Devi, K. Williams, Targeting GLI1 expression in human inflammatory breast cancer cells enhances apoptosis and attenuates migration. British Journal of Cancer 104 (2011) 1575-1586.[2] K.P. Williams, J.L. Allensworth, S.M. Ingram, G.R. Smith, A.J. Aldrich, J. Z Sexton, G. R Devi, Quantitative high-throughput efficacy profiling of approved oncology drugs in inflammat...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Oladapo, H., Fleming, J. M., Addo, K., Tarpley, M., Ehe, B., Ingram, S., Sauer, S., Devi, G., Williams, K. P. Tags: Experimental and Molecular Therapeutics Source Type: research

Abstract 3560: IFITM1 overexpression enhances the aggressive phenotype of inflammatory breast cancer in a STAT2-dependent manner
Inflammatory breast cancer (IBC) is a highly metastatic, aggressive, and fatal form of breast cancer that accounts for about 1 to 5% of all breast cancers diagnosed in the United States. At present, the molecular mechanisms that underlie the aggressive phenotype of IBC are not known. Interferon induced transmembrane protein1 (IFITM1) is a member of interferon stimulated genes (ISGs), whose overexpression has been linked to several malignancies, but its role in inflammatory breast cancer is not known. The primary role of IFITM1 is to stop the spread of viral pathogens in the host's cells, but its constitutive overexpression...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Ogony, J. W., Lewis-Wambi, J. Tags: Experimental and Molecular Therapeutics Source Type: research

Caveolin‐1 Mediates Inflammatory Breast Cancer Cell Invasion via the Akt1 Pathway and RhoC GTPase
This article is protected by copyright. All rights reserved
Source: Journal of Cellular Biochemistry - January 5, 2015 Category: Biochemistry Authors: Madhura Joglekar, Weam O. Elbazanti, Matthew D. Weitzman, Heather L. Lehman, Kenneth L. van Golen Tags: Article Source Type: research

Abstract C42: Quantitative high-throughput efficacy profiling of hedgehog/GLI pathway antagonists in inflammatory breast cancer
Conclusion: Several agents showed efficacy in in vitro IBC cancer models demonstrating that GLI inhibitors may be a valid therapeutic approach for targeting GLI-dependent IBC cancers.Funded in part by DOD/CDMRP IDEA W81XWH-13-1-0141(BC121850) (KP Williams)[1] W.F. Anderson, C. Schairer, B.E. Chen, K.W. Hance, P.H. Levine, Epidemiology of inflammatory breast cancer (IBC). Breast disease 22 (2006) 9-23.[2] W.A. Woodward, M. Cristofanilli, Inflammatory breast cancer. Seminars in Radiation Oncology 19 (2009) 256-265.[3] K.A. Hirko, A.S. Soliman, M. Banerjee, J. Ruterbusch, J.B. Harford, R.M. Chamberlain, J.J. Graff, S.D. Meraj...
Source: Cancer Epidemiology Biomarkers and Prevention - November 13, 2014 Category: Cancer & Oncology Authors: Oladapo, H., Ingram, S., Stefanowicz, A., Devi, G., Williams, K. Tags: Proteomics, Chemogenomics, and Chemoinformatics: Poster Presentations - Proffered Abstracts Source Type: research